1. Home
  2. OBK vs ZYME Comparison

OBK vs ZYME Comparison

Compare OBK & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBK
  • ZYME
  • Stock Information
  • Founded
  • OBK 1912
  • ZYME 2003
  • Country
  • OBK United States
  • ZYME United States
  • Employees
  • OBK N/A
  • ZYME N/A
  • Industry
  • OBK Major Banks
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • OBK Finance
  • ZYME Health Care
  • Exchange
  • OBK Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • OBK 1.2B
  • ZYME 968.5M
  • IPO Year
  • OBK 2018
  • ZYME 2017
  • Fundamental
  • Price
  • OBK $38.62
  • ZYME $15.05
  • Analyst Decision
  • OBK Buy
  • ZYME Buy
  • Analyst Count
  • OBK 7
  • ZYME 7
  • Target Price
  • OBK $43.00
  • ZYME $20.00
  • AVG Volume (30 Days)
  • OBK 105.0K
  • ZYME 465.9K
  • Earning Date
  • OBK 10-22-2025
  • ZYME 10-30-2025
  • Dividend Yield
  • OBK 1.53%
  • ZYME N/A
  • EPS Growth
  • OBK N/A
  • ZYME N/A
  • EPS
  • OBK 2.23
  • ZYME N/A
  • Revenue
  • OBK $340,866,000.00
  • ZYME $122,867,000.00
  • Revenue This Year
  • OBK $12.81
  • ZYME $107.76
  • Revenue Next Year
  • OBK $7.25
  • ZYME $2.35
  • P/E Ratio
  • OBK $17.52
  • ZYME N/A
  • Revenue Growth
  • OBK N/A
  • ZYME 95.94
  • 52 Week Low
  • OBK $28.80
  • ZYME $9.03
  • 52 Week High
  • OBK $41.17
  • ZYME $17.70
  • Technical
  • Relative Strength Index (RSI)
  • OBK 58.41
  • ZYME 62.01
  • Support Level
  • OBK $38.05
  • ZYME $13.60
  • Resistance Level
  • OBK $39.23
  • ZYME $15.35
  • Average True Range (ATR)
  • OBK 0.71
  • ZYME 0.61
  • MACD
  • OBK 0.09
  • ZYME -0.01
  • Stochastic Oscillator
  • OBK 71.45
  • ZYME 82.63

About OBK Origin Bancorp Inc.

Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: